



TriMark Publications

July 2014
Volume: TMRUSGT14-0701

U.S. GLUCOSE TESTING MARKETS

(SAMPLE COPY, NOT FOR RESALE)

Trends, Industry Participants, Product Overviews and Market Drivers

TABLE OF CONTENTS

1.	Overview	11
1.1	Statement of Report	11
1.2	About This Report	11
1.3	Scope of the Report	12
1.4	Methodology	13
1.5	Executive Summary	14
2.	Diabetes	17
2.1	Demographics of Diabetes in the U.S.	18
2.2	Understanding the Metabolic Conditions Underlying and Associated with Diabetes	23
2.2.1	Pre-Diabetes Syndrome	24
2.2.2	Metabolic Syndrome	24
2.2.3	Progression of Diabetes	24
2.2.4	Diabetes and Inflammation	25
2.2.5	Risk Factors and Diabetes	25
2.2.5.1	Obesity	26
2.2.5.2	Stress-Induced Hyperglycemia	28
2.2.6	Complications and Co-Morbidities in Diabetes	29
2.2.6.1	Preventing Complications and Co-Morbidities in Diabetes	33
2.2.6.2	Cardiovascular Disease Facts	34
2.3	Economics of Diabetes	37
3.	Market Analysis: Size, Growth, Share and Competitors	43
3.1	U.S. Market	44
3.1.1	U.S. Over-the-Counter (OTC) Self-Testing Glucose Market	45
3.1.2	U.S. Professional Glucose Testing Market	50
3.1.3	Continuous Glucose Monitoring Markets	51
3.2	Competitive Situation	52
3.2.1	Key Players	52
3.2.2	Analyses of the Self-Testing Market Conditions, Competition and Product Mix	52
3.2.3	Analyses of the Professional Blood Glucose Monitoring Market	55
3.3	Market Drivers and Restraints	57
3.3.1	Market Drivers	57
3.3.2	Market Restraints	59
3.4	Market and Product Trends	61
3.4.1	Market Trends	61
3.4.2	Technology Trends	62
3.5	Strategic Recommendations	63
3.6	Competitive Strategies	65
3.7	New Opportunities in the Professional Blood Glucose Meter Market	66
3.8	Adjacent Markets	67
4.	Glucose Diagnostic and Monitoring Recommendations	68
4.1	Diagnosis of Diabetes Mellitus	68
4.2	Tight Glucose Control in Treating Diabetes	71
4.2.1	Tight Glucose Control Lowers Cardiovascular Complications	72
4.3	Recommendations for Glucose Control in Diabetics	72
4.3.1	Recommended Frequency of Blood Glucose Self-Testing	74
4.3.2	Using Blood Glucose Data to Monitor and Modify Patient Therapy	75
4.3.3	Testing in Individuals with Type 2 Diabetes	76
4.3.4	Continuous Glucose Monitoring (CGM)	77
4.3.5	A1c Testing Recommendations	78
4.3.6	Recommendations for Diabetes Care and Glucose Testing in the Hospital Setting	78
4.4	Hypoglycemia and Treatment	82

5.	Glucose Testing Technology Platforms and Consumable Products	84
5.1	Types of Glucose Determination Technologies	84
5.2	Enzymatic Reactions Used to Determine Glucose Concentrations	85
5.2.1	Glucose Oxidase (GOX)	85
5.2.2	Glucose Dehydrogenase (GDH)	86
5.2.2.1	GDH-NAD (Glucose Dehydrogenase-Nicotinamide Adenine Dinucleotide)	86
5.2.2.2	GDH-FAD (Glucose Dehydrogenase-Flavin Adenine Dinucleotide)	86
5.2.2.3	GDH-PQQ (Glucose Dehydrogenase-Pyrroloquinoline Quinone)	86
5.2.3	Glucose Hexokinase	86
5.3	Development of Blood Glucose Monitors: A Historical Evaluation	87
5.3.1	First-Generation Blood Glucose Biosensors	87
5.3.2	Second-Generation Blood Glucose Biosensors	87
5.3.3	Third-Generation Blood Glucose Biosensor	87
5.4	Accuracy and Precision in Glucose Meters	88
5.4.1	Clinical and Laboratory Standards Institute (CLSI) POCT12-A3	89
5.4.2	International Organization for Standardization (ISO) 15197:2013	90
5.4.3	FDA Guidelines for Blood Glucose Testing Systems	90
5.4.4	Determining Clinical Accuracy Using the Error Grid Analysis (EGA)	93
5.4.5	Quality Control Criteria	94
5.4.6	Potential Variables Affecting Glucose Concentrations	95
5.5	Key Issues for Glucose Testing Devices	95
5.5.1	Important Elements for Glucose Testing	96
5.5.2	Key Features to Aid Specific Patient Populations	97
5.6	Limitations of Existing Glucose Testing	98
5.6.1	Common User Errors in Glucose Self-Testing	99
5.6.2	Interfering Substances and Conditions	100
5.6.2.1	Environmental	100
5.6.2.2	Physiologic	100
5.6.2.3	Operational	100
5.6.2.4	Manufacturing Variations	100
5.6.2.5	Drugs/Medications	100
5.6.2.6	Patient Factors	100
5.6.3	Errors Associated with GDH-PQQ Technology	101
5.6.4	Optimizing of Point of Care (POC) Blood Glucose Testing	104
5.7	Potential Areas of Improvement in Blood Glucose Meter Performance	104
5.8	Blood Glucose Reagent Test Strips	106
5.9	Comparison of Hand-Held Blood Glucose Meters with Clinical Laboratory Glucose Measurements	107
5.10	Continuous Glucose Monitoring Technology	108
5.10.1	Advantages of Continuous Readings	108
5.10.2	FDA Approval of CGM	108
5.10.3	CGM Functions to Consider	109
5.10.4	New Technologies for CGM	110
5.11	Summary of Technologies Being Explored for Non-Invasive Glucose Monitoring	110
5.11.1	GlucoTrack	110
5.11.2	Non-Invasive Glucose Monitoring Technologies in Development	111
5.11.3	Goals of Non-Invasive Testing	112
5.11.4	Non-Invasive Diabetes Screening Test	112
5.12	A1c Monitoring Technology	113
5.13	Fructosamine Test	114
5.14	Related Reagents and Equipment	115
5.14.1	Lancets	115
5.14.1.1	Types of Lancing Devices	116
5.14.1.2	Market Size	116
5.14.2	Control Solutions and Calibrators	121

5.14.3	Sharps Devices	121	
5.14.4	Needle Destruction Devices	122	
5.14.5	Urine Strips	122	
5.14.6	Ketone Testing	124	
5.14.7	Long-Term Glucose Sensing Bio-Implants	125	
6.	Glucose Testing Devices on the Market	126	
6.1	Hand-held Blood Glucose Meters and Strips for Self-Testing	126	
6.1.1	LifeScan, Inc.	129	
6.1.2	Roche Diagnostics Corporation	132	
6.1.3	Bayer	133	
6.1.4	Abbott	135	
6.1.5	Agamatrix, Inc.	137	
6.1.6	Arkray, Inc.	138	
6.1.7	Bionime Corporation	139	
6.1.8	BioSense Medical Devices	141	
6.1.9	CVS/Pharmacy	141	
6.1.10	Diabetic Supply of Suncoast	141	
6.1.11	Entra Health Systems	142	
6.1.12	Fifty50 Pharmacy	142	
6.1.13	Fora Care	142	
6.1.14	Genesis Health Technologies	143	
6.1.15	GlucoCom	143	
6.1.16	Infopia	144	
6.1.17	Nipro Diagnostics, Inc.	144	
6.1.18	Nova Biomedical	146	
6.1.19	Oak Tree International Holdings, Inc.	146	
6.1.20	Omnis Health	146	
6.1.21	Phylosis	147	
6.1.22	Prodigy Diabetes Care, LLC (an affiliate of Diagnostic Devices, Inc.)	147	
6.1.23	Sanofi	148	
6.1.24	Target	148	
6.1.25	Telcare	148	
6.1.26	Tyson Biomedical	148	
6.1.27	US Diagnostics	149	
6.1.28	Walgreens	150	
6.1.29	Walmart	150	
6.1.30	77 Elektronika Kft.	150	
6.1.31	A. Menarini Diagnostics	150	
6.1.32	All Medicus	151	
6.1.33	i-SENS	151	
6.1.34	Apex Biotechnology Corp.	151	
6.1.35	Glucoplus, Inc.	152	
6.1.36	Polymer Technology Systems	152	
6.1.37	Smiths Medical MD, Inc.	152	
6.1.38	TaiDoc Technology Corp.	152	
6.1.39	IN4 Technology Corporation	152	
6.1.40	ACON Laboratories, Inc.	152	
6.1.41	Pepex Biomedical	153	
6.1.42	HMD BioMedical	153	
6.1.43	BTNX, Inc.	154	
6.1.44	Shasta Technologies and Decision Diagnostics Corporation	154	
6.2	Hand-held Blood Glucose Meters for Professional Use	154	
6.2.1	Abbott	156	
6.2.1.1	Precision Xceed Pro Blood Glucose and Beta-Ketone Monitoring System	156	
6.2.1.2	i-STAT System	157	

6.2.2	ACON Laboratories	157	
6.2.2.1	On Call Platinum Blood Glucose Monitoring System		157
6.2.3	Alere	157	
6.2.3.1	epoc Blood Analysis System	157	
6.2.3.2	Alere Cholestech LDX System	158	
6.2.4	ARKRAY, Inc.	158	
6.2.4.1	Assure Platinum, Assure Pro, and Assure 4		158
6.2.5	EKF Diagnostics	158	
6.2.5.1	Biosen Series of Glucose and Lactate Analyzers	158	
6.2.6	HemoCue (a Quest Diagnostics Company)	158	
6.2.6.1	HemoCue Glucose 201 and Glucose 201 DM Systems		159
6.2.7	HMD BioMedical	159	
6.2.7.1	NS100	159	
6.2.8	Medtronic	159	
6.2.8.1	iPro Continuous Glucose Monitor		159
6.2.9	Nova Biomedical	159	
6.2.9.1	StatStrip Hospital Glucose Monitoring System		159
6.2.10	Polymer Technology Systems, Inc.	160	
6.2.10.1	CardioChek PA Point of Care Device	160	
6.2.11	Roche	160	
6.2.11.1	Accu-Chek Inform II System	160	
6.2.11.2	Accutrend Plus System	160	
6.2.12	Techno Medica Co., Ltd.	161	
6.2.12.1	GASTAT-mini	161	
6.2.13	LifeScan	161	
6.3	Clinical Blood Chemistry Analyzers	161	
6.3.1	Abaxis, Inc.	163	
6.3.2	Alere	163	
6.3.3	ARKAY, Inc.	164	
6.3.4	Beckman Coulter	164	
6.3.5	DiaSys	164	
6.3.6	Instrumentation Laboratory	165	
6.3.7	International Techidyne Corporation (ITC)		165
6.3.8	Nova Biomedical	165	
6.3.9	Radiometer	166	
6.3.10	Randox Laboratories	167	
6.3.11	Roche	168	
6.3.12	Siemens Healthcare Diagnostics	168	
6.3.13	Span Diagnostics	171	
6.3.14	Stanbio Laboratory	171	
6.3.15	Techno Medica Co., Ltd.	171	
6.3.16	YSI Life Sciences	171	
6.4	Continuous Glucose Patient Monitoring Systems	172	
6.4.1	Medtronic's Continuous Glucose Monitoring Systems (CGMS)		173
6.4.2	DexCom, Inc. G4 Platinum Continuous Glucose Monitoring System		176
6.4.3	FreeStyle Navigator—Abbott's Continuous Glucose Monitor System		177
6.4.4	GlucoDay S Continuous Glucose Monitor	178	
6.4.5	Minimally-Invasive Continuous Glucose Monitors in Development		178
6.4.5.1	GlySens, Inc.	178	
6.4.5.2	Senseonics (formerly Sensors for Medicine and Science)		179
6.4.5.3	Ultradian	179	
6.4.5.4	GluMetrics	179	
6.4.5.5	GlySure Limited	180	
6.5	Non-Invasive Glucose Patient Monitoring Systems	180	
6.5.1	Cygnus GlucoWatch Biographer	181	
6.5.2	AiMedics	181	

6.5.3	BioTex, Inc.	182	
6.5.4	Echo Therapeutics, Inc.	182	
6.5.5	EyeSense GmbH	183	
6.5.6	Freedom Meditech	183	
6.5.7	Grove Instruments	183	
6.5.8	Integrity Applications Ltd.	183	
6.5.9	LighTouch Medical, Inc.	184	
6.5.10	OrSense Ltd.	184	
6.5.11	VeraLight, Inc.	185	
6.5.12	Xhale, Inc.	185	
6.5.13	Lein Applied Diagnostics	185	
6.6	A1c Testing	185	
6.7	New Product Launches	186	
6.7.1	OneTouch Verio Sync Blood Glucose Monitoring System	186	
6.7.2	Medtronic's MiniMed 530G with Enlite Sensor Technology	186	
6.7.3	Contour Next Link Meter Approved for Use with Medtronic's New MiniMed 530G with Enlite Insulin Pump System	187	
6.7.4	Roche's ACCU-CHEK Inform II System Approved by the FDA	187	
6.7.5	Abbott Receives CE Mark for FreeStyle Optium Neo Blood Glucose and Ketone Monitoring System	187	
6.7.6	Abbott Receives FDA Clearance for FreeStyle Precision Pro Blood Glucose and β -Ketone Monitoring System	187	
6.7.7	LabStyle Innovations' Dario Diabetes Management System	187	
6.7.8	BlueStar by WellDoc	188	
6.7.9	FDA Approves Bayer's Contour Next EZ	188	
6.7.10	Glooko Received its Second 510(k) Clearance for Glucose Monitoring Logbook App	188	
6.7.11	Sanofi-Aventis's iBGStar	189	
6.7.12	iHealth Glucose Meter Device	189	
6.7.13	MyGlucoHealth Diabetes	189	
6.7.14	gDrive	190	
6.7.15	Shasta GenStrips	190	
6.7.16	mySentry Remote Glucose Monitor	190	
6.7.17	OneTouch Verio IQ System with PatternAlert Technology	190	
6.7.18	Accu-Chek Nano SmartView	190	
6.8	Blood Glucose Meters, CGMs, and Data Management Software in Development	190	
6.8.1	Abbott's Flash Glucose Monitoring System	190	
6.8.2	Google Announces Plan to Create Contact Lens Glucose Sensors	191	
6.8.3	Socrates Health Solutions' Companion Blood Glucose Monitor	191	
6.8.4	DexCom and Johnson and Johnson's Animas Working to Develop an Artificial Pancreas	191	
6.8.5	Medtronic Enrolling Patients into Trial Testing Third-Generation, Fully-Automated Artificial Pancreas	191	
6.8.6	Boston University's Bionic Pancreas Project	191	
6.9	Recent Industry Activity	191	
6.9.1	Roche Diagnostics Corp. Cutting Jobs in Diabetes Division	191	
6.9.2	AgaMatrix and Sanofi-Aventis Enter Global Diabetes Partnership	191	
6.9.3	LifeScan, Inc. Terminates Exclusive Supply Agreement with Medtronic MiniMed	192	
6.9.4	Kroger Selects WaveSense Diabetes Testing Products	192	
6.9.5	Medtronic and Bayer Healthcare Expand International Alliance	192	
6.9.6	PositiveID Corporation and IDEAL LIFE Partner to Bring iglucose to Market for Wireless Diabetes Management	192	
6.9.7	Roche Diagnostics U.S. and DexCom, Inc. Announce Research and Development Agreement	192	
6.9.8	BD and JDRF Collaborating on a Device Using a Single Infusion Catheter for Both CGM and Pump	193	
6.9.9	Court Sides with Decision Diagnostics in Patent Infringement Case	193	
6.9.10	iBGStar Blood Glucose Monitoring System Receives U.S. FDA 510(k) Clearance	193	
6.9.11	Infopia America Partners with Walgreens Drugstores	193	

6.9.12	Qualcomm Forms Qualcomm Life Subsidiary	193	
6.9.13	Perrigo and AgaMatrix Enter into an Exclusive Sales and Distribution Agreement	194	
6.9.14	Pepex Biomedical Signs Seven Year Deal to Manufacture Trio	194	
6.9.15	DexCom and Tandem Diabetes Care Team Up for CGM Development and Commercialization	194	
6.9.16	Insulet Corporation Signs Worldwide Agreement with LifeScan	194	
6.10	M&A Activity	194	
6.10.1	Home Diagnostics, Inc. and Nipro Diabetes Systems, Inc. Merge to Become Nipro Diagnostics, Inc.	194	
6.10.2	Medtronic, Inc. (MDT) Acquires New Diabetes Technology from PreciSense AS	195	
6.10.3	Geonostics Acquires FlexSite's Consumer Diabetes Tests	195	
6.10.4	Radiometer Medical Acquires Hemocue	195	
6.10.5	Additional M&A	195	
6.10.6	Important Deals in BGM market	196	
7.	Business Trends in Glucose Testing	198	
7.1	Drivers of Clinical Glucose Testing	198	
7.2	Competition for Services	198	
7.3	Healthcare Cost Controls	198	
7.4	Changes in Patient Management	199	
7.5	Regionalization of Laboratory Care	199	
7.6	Satellite Facilities	200	
7.7	Professional Point of Care Testing	200	
7.8	Factors Affecting OTC Medical Product Distribution	201	
7.9	Drugstores Critical to the Diabetic Care Category	203	
7.10	Drivers of OTC and Self-Testing Markets	203	
7.10.1	Brand Loyalty	203	
7.11	Cost Elements of Glucose Self-Testing	204	
7.12	Blood Glucose Self-Testing Insurance Coverage and Reimbursement	204	
7.13	Reimbursement Challenges	207	
7.13.1	New Medicare Part B	208	
7.14	Managed Care	208	
7.15	Government Regulation of Medical Devices	208	
7.16	Clinical Laboratory Improvement Act (CLIA)	211	
7.17	FDA Labeling Requirements	213	
7.18	Legal Liability for Glucose Meters	214	
7.19	FDA's Artificial Pancreas Guidance Document	215	
8.	Technology Trends	216	
8.1	Improving Today's OTC Blood Glucose Meters	216	
8.2	Biosensor Technology	217	
8.3	Fructosamine Test	219	
8.4	Telemedicine Devices	219	
8.4.1	Remote Patient Monitoring	222	
8.4.1.1	Infopia Eocene System	225	
8.4.1.2	Health Buddy Systems Monitoring Technologies	226	
8.4.1.3	GlucoCom Glucose Monitoring System	226	
8.4.1.4	Alere's DayLink Monitor	226	
8.4.1.5	Alere HomeLink Receives FDA Approval for Over-the-Counter Use	226	
8.5	Non-Traditional Methods for Sample Collection	227	
8.6	Data Management	227	
8.6.1	Medical Device Radiocommunications Service (MedRadio)	227	
8.6.2	Connectivity	228	
8.6.3	Advantages of Connectivity	229	
8.6.4	Connectivity Platforms	230	
8.6.5	DataLink Data Management System	230	
8.6.6	RALS-Plus	232	

8.6.7	FDA Required Software Verification	232	
8.6.8	Information Management Advances	232	
8.6.9	POL Laboratory Data Management	234	
8.6.9.1	Electronic Medical Record Systems and Physician Office Laboratory Data Linking Software		234
8.6.9.2	Physician Office Laboratory Data Linking Software and Interface to the Laboratory Information System	236	
8.6.9.3	Technical Problems of Connectivity	236	
8.6.9.4	Web-Based Data Interface	237	
8.6.10	HIT Competition	237	
9.	Company Profiles	238	
9.1	Abaxis, Inc.	238	
9.2	Abbott Laboratories	240	
9.3	ACON Laboratories	243	
9.4	AgaMatrix	244	
9.5	Alere, Inc.	244	
9.6	All Medicus, Co., Ltd.	244	
9.7	Amedica Biotech	244	
9.8	A. Menarini Diagnostics	245	
9.9	Apex Biotechnology Corporation	245	
9.10	ARKRAY USA, Inc.	245	
9.11	Bayer AG	245	
9.12	B. Braun Melsungen	247	
9.13	Beckman Coulter	247	
9.14	Bionime	252	
9.15	Bio-Rad Laboratories, Inc.	252	
9.16	BioTex, Inc.	253	
9.17	Calisto Medical, Inc.	253	
9.18	Cambridge Sensors	253	
9.19	DexCom	253	
9.20	Diagnostic Devices/Prodigy Diabetes Care		255
9.21	DiaSys	255	
9.22	Echo Therapeutics, Inc.	255	
9.23	Entra Health Systems	257	
9.24	Fora Care	257	
9.25	FIFTY50 Medical, Inc.	257	
9.26	Freedom Meditech	257	
9.27	Genesis Health Technologies	257	
9.28	GenExel-Sein, Inc.	257	
9.29	GlucoPlus	257	
9.30	GlySens, Inc.	258	
9.31	GlySure Limited	258	
9.32	Grove Instruments	258	
9.33	Hainice Medical	258	
9.34	HemoCue (a Quest Diagnostics company)	258	
9.35	Home Diagnostics	259	
9.36	Infopia Co., Ltd.	259	
9.37	IN4 Technology	259	
9.38	International Techidyne Corporation (ITC)		259
9.39	Instrumentation Laboratory Company	260	
9.40	i-Sens	260	
9.41	Johnson & Johnson	260	
9.42	LabStyle Innovations Corporation	261	
9.43	Medtronic	262	
9.44	Nipro Diagnostics	263	
9.45	Nova Biomedical	263	

9.46	OrSense Ltd.	263	
9.47	Polymer Technology Systems	263	
9.48	Prodigy Diabetes Care, LLC (formerly Diagnostic Devices, Inc.)	264	
9.49	Radiometer Medical	264	
9.50	Roche Diagnostics	265	
9.51	77 Elektronika Kft.	266	
9.52	Siemens AG	266	
9.53	Smiths Group	266	
9.54	Stanbio Laboratory	267	
9.55	TaiDoc Technology	267	
9.56	Techno Medica Co., Ltd.	268	
9.57	Telcare	268	
9.58	US Diagnostics	268	
9.59	VeraLight	268	
9.60	Ypsomed Holding	268	
9.61	YSI Life Sciences	269	

INDEX OF FIGURES

Figure 2.1: Annual Number of New Cases of Diagnosed Diabetes Among U.S. Adults Aged 18-79 Years, 1980-2011	19
Figure 2.2: Diagnosed Diabetes by Age in the U.S., 2013	19
Figure 2.3: Number of Deaths from Diabetes by Age in the U.S., 2010	22
Figure 2.4: Number of Diabetes Deaths by Race and Sex in the U.S., 2010	22
Figure 2.5: Maintenance of Normal Blood Sugar Levels	23
Figure 2.6: Prevalence of Self-Reported Obesity (BMI \geq 30) Among U.S. Adults, 2012	27
Figure 2.7: Prevalence of Obesity Among Adults in the U.S., 2009-2010	27
Figure 2.8: Trends in Obesity Among Children and Adolescents in the U.S., 1988-2010	28
Figure 2.9: Age-Adjusted Percentage of People with Diabetes Aged 35 Years or Older Reporting Heart Disease or Stroke, by Sex, in the U.S., 1997-2011	30
Figure 2.10: Percentage of Adults with Diagnosed Diabetes Reporting Any Mobility Limitation, by Age, in the U.S., 1997-2011	32
Figure 2.11: Number (in Millions) of Adults Aged 18 Years or Older with Diagnosed Diabetes Reporting Visual Impairment, in the U.S., 1997-2011	33
Figure 2.12: How Diabetes Dollars are Spent in the U.S., 2012	39
Figure 2.13: Percent of Medical Condition-Specific Expenditures Associated with Diabetes, 2012	41
Figure 3.1: Forecasted Test Strip Usage by Different Diabetic Populations	46
Figure 4.1: Approach to Management of Hypoglycemia	74
Figure 4.2: Glycemic Status—Ranges and Health Implications	79
Figure 5.1: EGA Zones of Clinical Accuracy	94
Figure 5.2: Single-Day Continuous Blood Glucose Data	99
Figure 5.3: Factors that may Adversely Affect Glucose Testing	101
Figure 5.4: Personal Lancet Unit Sales Market Share by Geographic Region, 2013	118
Figure 6.1: Medtronic's Threshold Suspend Feature	175

INDEX OF TABLES

Table 2.1: U.S. Population of Diagnosed Diabetics Aged 20-79 Years, 2013	20
Table 2.2: Percentage of U.S. Adults with Diagnosed Diabetes by State, 2010	20
Table 2.3: Ten Leading Diagnoses for Co-Morbid Chronic Diseases in the U.S.	29
Table 2.4: Odds Ratio of Progression to Complications Associated with Type 2 Diabetes	31
Table 2.5: Prevalence of Complications Among Patients with Diabetes	31
Table 2.6: Major Causes of End-Stage Renal Disease	31

Table 2.7: Novel Risk Factors and Possible Mechanisms of the Excess Risk of Coronary Heart Disease in Type 2 Diabetes Mellitus	32
Table 2.8: Clinical Recommendations for Adults with Diabetes	34
Table 2.9: Laboratory Assessment of Diabetic Vascular Disease	34
Table 2.10: Average Years Gained Free of Diabetes-Related Disease with Intensive Management	34
Table 2.11: Estimated Direct and Indirect Costs of Major Cardiovascular Diseases and Stroke in the U.S., 2010	36
Table 2.12: Cost of Diagnosed Diabetes in the U.S., 2012	38
Table 2.13: Annual Cost of Care of United Healthcare Adult Members with Diabetes, 2009	40
Table 2.14: Healthcare Utilization by Diabetic Patients, 2012	40
Table 3.1: Comprehensive Glucose Testing Market in the U.S. (Includes Reagents and Supplies in the Self-Testing and Professional Markets), 2012-2018	45
Table 3.2: U.S. Blood Glucose Reagent Strip Market (Includes Both Self-Testing and Professional Markets), 2012-2018	45
Table 3.3: Market for Glucose Self-Testing in the U.S. (Includes Meters, Strips and Lancets), 2012-2018	46
Table 3.4: Market Share of U.S. Blood Glucose Self-Testing, 2013	47
Table 3.5: U.S. OTC Glucose Self-Testing Market Repeat Retail Replacement Sales Percentages	47
Table 3.6: OTC Blood Glucose Instrument Reagents by Manufacturer Retail	48
Table 3.7: Demographic Characteristics Glucose Self-Testing Kit Buyers	49
Table 3.8: Top Brand Preferences for Glucose Self-Testing Kits	49
Table 3.9: Instances when Patients Prefer Professional's Glucose Testing	49
Table 3.10: Advantages of a Glucose Self-Testing Kit	49
Table 3.11: Disadvantages of Using a Glucose Self-Testing Kit	50
Table 3.12: Popular Shopping Destinations for Buying or Seeking Information on Glucose Self-Testing Kits	50
Table 3.13: Customer Priorities—Glucose Meter Self-Testing Market, 2001, 2006 and 2013	50
Table 3.14: Market for Total Professional Glucose Testing (Central Laboratory and Hospital POC & POL) in the U.S., 2012-2018	51
Table 3.15: U.S. Revenues for Professional POC Blood Glucose Monitoring (Hospital & POL), 2012-2018	51
Table 3.16: U.S. Continuous Glucose Monitoring Market, 2012-2018	51
Table 3.17: SWOT Analysis: Summary of Strengths, Weaknesses, Opportunities and Threats of the Glucose Point of Care Market	57
Table 3.18: Key Market Drivers for Glucose Testing	58
Table 3.19: Point of Care Glucose Testing Market: Market Drivers Ranked in Order of Impact	58
Table 3.20: Market Drivers for Continuous Glucose Monitoring	59
Table 3.21: Key Market Restraints for Glucose Testing	60
Table 3.22: Market Restraints for Continuous Glucose Monitoring	60
Table 3.23: Point of Care Glucose Testing Market: Market Restraints Ranked in Order of Impact	60
Table 4.1: Criteria for the Diagnosis of Diabetes	68
Table 4.2: Categories of Increased Risk for Diabetes (Pre-Diabetes)	68
Table 4.3: Normal Glucose Values—Fasting State	69
Table 4.4: Criteria for Testing for Diabetes in Asymptomatic Adults	69
Table 4.5: Criteria for Type 2 Diabetes in Asymptomatic Children	70
Table 4.6: Screening for and Diagnosis of Gestational Diabetes Mellitus (GDM)	71
Table 4.7: Glycemic Recommendations for Non-Pregnant Adults with Diabetes	73
Table 4.8: Glycemic Recommendations for Women with Gestational Diabetes	73
Table 4.9: Glycemic Recommendations for Pregnant Women with Pre-Existing Diabetes	73
Table 4.10: Plasma Blood Glucose and A1c Goals for Type 1 Diabetes by Age-Group	73
Table 4.11: Glucose Monitoring Recommendations	75
Table 4.12: Key Issues for SMBG in Insulin-Independent Type 2 Diabetics	76
Table 4.13: A1c Testing Recommendations	78
Table 4.14: Correlation of A1c with Mean Blood Glucose	78
Table 4.15: Glucose Monitoring Recommendations for Hospital Settings	80
Table 4.16: Glycemic Goals for Hospital Patients	81
Table 5.1: Analytic Performance Criteria for Glucose Meters	89

Table 5.2: Potential Variables Affecting Glucose Concentrations	95	
Table 5.3: Key Features Considered for Glucose Testing Devices	97	
Table 5.4: Common User Errors Made While Self-Testing for Blood Glucose	99	
Table 5.5: Compatibility of Various Blood Glucose Meters with Icodextrin PD Solution		102
Table 5.6: Ten Factors Needed to Improve the Performance of Blood Glucose Meters	104	
Table 5.7: Features Required for Safe and Effective Meters for Hospital Settings	105	
Table 5.8: Key Features Considered for Reagent Test Strips	107	
Table 5.9: Differences between Laboratory Instruments for Glucose Analysis and Hand-Held Blood Glucose Meters	107	
Table 5.10: Relationship of A1c to Average Whole Blood and Plasma Glucose Levels	113	
Table 5.11: Unit Sales of Homecare Lancets in the U.S., 2012-2017	117	
Table 5.12: Unit Sales of Homecare Lancets in the E.U., 2012-2017	117	
Table 5.13: Dollar Sales of Homecare Lancets in the U.S., 2012-2017	117	
Table 5.14: Dollar Sales of Homecare Lancets in the E.U., 2012-2017	118	
Table 5.15: Unit Sales of Homecare Glucose Self-Testing Lancets in the U.S., 2012-2017		118
Table 5.16: Unit Sales of Homecare Glucose Self-Testing Lancets in the E.U., 2012-2017		118
Table 5.17: Competition in the Lancet Market Segment	119	
Table 5.18: Limitations of Urine Glucose Monitoring	123	
Table 5.19: Advantages of Urine Glucose Monitoring	123	
Table 5.20: Blood Ketone Reading Indications	124	
Table 6.1: Current Blood Glucose Self-Testing Meters: Sample Size, Test Time, and Other Features		126
Table 6.2: Point of Care Blood Glucose or Blood Gas Meters Marketed for Professional Use	155	
Table 6.3: Clinical Blood Chemistry Analyzers with Glucose Assays	162	
Table 6.4: Detailed Features of Selected CGM Systems Currently Available	173	
Table 6.5: Non-Invasive Glucose Monitoring Systems in Development	181	
Table 7.1: POC Procedural Advantages for Hospital Testing	198	
Table 7.2: Financial Comparison for Moderate and Waived CLIA Labs	212	
Table 8.1: Data Entry and Data Management Features to Include in Future Meters		217
Table 8.2: Leading Companies for Patient Monitoring Products	225	
Table 8.3: Customized Reports Must Support CAP and JCAHO Requirements		232

1. Overview

1.1 Statement of Report

U.S. glucose testing is undergoing a significant transition, driven by new analytical technologies and developments in diabetes treatment. Although the blood glucose testing segment of the *in vitro* diagnostics (IVD) industry is mature, the home testing devices for diabetes management continues to be significant market force due to its large size. Direct access testing, or self-testing, is an important segment in the blood glucose testing market, and non-invasive and minimally-invasive testing now represent major new areas for the application of IVD testing. This TriMark Publications report describes the specific market segments for blood glucose testing for diabetes management in the U.S. market. It reviews all of the generally-accepted clinical analytical methods that are currently in use today for measuring serum, plasma or whole-blood glucose concentrations. Additionally, this study examines clinical measurement devices, reagents, and supplies as utilized in hospitals, clinics, doctor's offices, and at-home care locations. Moreover, it analyzes almost all of the companies known to be marketing, manufacturing or developing glucose testing products for the U.S. market.

1.2 About This Report

The main objectives of this analysis are:

- Identifying viable technology drivers through a comprehensive look at platform technologies for glucose testing for diabetes management.
- Understanding the different sectors of glucose testing, such as the home self-testing and the professional glucose testing segments.
- Obtaining a complete understanding of the individual glucose testing platforms from their basic principles to their clinical applications.
- Discovering feasible market opportunities by identifying high-growth applications in different analytical diagnostic areas.
- Focusing on industry development through an in-depth analysis of the U.S. market for glucose measurement technology, including growth forecasts.
- Presenting U.S. market figures regarding the current value of blood glucose testing, market projections, market share, key players, and sector growth rates.
- Providing a detailed analysis of each of the major device categories, such as blood glucose meters (including non- and minimally-invasive), blood glucose meter test strips, lancets and lancing devices, and urine glucose/metabolite monitoring strips.

This analysis defines the dollar volume of market sales in the U.S. and analyzes the factors that influence the size and the growth of the market segments. Key questions answered in this examination include:

- How can glucose measuring tools and technologies facilitate improved diabetes patient care?
- What are the main types of glucose testing technologies that are currently available?
- Who are the current key players in this marketplace?
- Which glucose testing market areas have the greatest potential for growth?
- What is the current state of the glucose testing market?
- Which diagnostic companies are investing in new glucose testing technology platform solutions?
- What are the main business strategies adopted by leading glucose testing companies?
- What are the benefits of various glucose testing technology platforms?

Additionally, this study contains:

- Detailed analysis of recent trends in the glucose testing marketplace.
- In-depth profiles of the leading companies with glucose testing tools and technologies.
- Perspectives of the glucose testing industry from leading industry experts.
- Analysis of potential new glucose testing applications in the clinical sector as they pertain to diabetes management.

- Market predictions and trends analysis concerning U.S. expenditures on glucose testing solutions.
- Projections of the U.S. glucose testing market size.
- Projections for future applications of non-invasive tests in glucose testing-related screening.
- Review of commercial glucose testing business strategies such as co-branding.

Analysis includes charts and graphs measuring product growth and trends within the marketplace. Company-specific information—including sales figures, product pipeline status, and R&D trends—is provided. Also, this review includes:

- Assessment of glucose testing market drivers and bottlenecks, from medical and scientific community perspectives.
- Discussions on the potential benefits of glucose testing for various sectors of the medical and scientific community, as they relate to diabetes management.
- The current total market size and future growth of the U.S. glucose testing market and analysis of the current size and growth of individual segments.
- Current and forecasted market shares by companies.
- Discussions on profit and business opportunities by segments.
- Strategic recommendations for near-term business opportunities.
- Analysis of the current commercial uses of glucose testing for diabetes management.

The following questions will also be addressed in this report:

- What are the near-term business opportunities in the U.S. glucose testing market?
- What are the current and forecasted glucose testing market sizes in the U.S.?
- What are the business models currently used by companies in the glucose testing market?
- How will manufacturers, researchers, physicians and patients influence diabetes management?
- What are the drivers and bottlenecks influencing the glucose testing market?
- What are the barriers to entry for the glucose testing market?
- What are the key technologies used in glucose testing?
- Who holds the proprietary rights to the glucose testing market technology platforms?
- How is this technology currently being applied and utilized?
- What regulatory processes apply to glucose testing technologies in the U.S.?

1.3 Scope of the Report

This analysis emphasizes companies that are actively developing and marketing instrumentation, reagents and supplies for performing glucose tests in the U.S. Specific attention is paid to the clinical market segment and, separately, to the instruments, reagents, and supplies marketed by major companies for the home self-testing market for diabetes management. Market size, growth rates and market components for instruments, reagents, controls, and consumables used in this area are also analyzed. Activity and trends in research, including patterns of information processing in array testing instruments, are addressed. Also discussed are trends that have stimulated this market and the numbers of institutions that use glucose testing and the factors that influence purchasing.

This report surveys all companies known to be marketing, manufacturing or developing instruments and reagents for the glucose testing market, and delineates the major market segments of professional glucose testing and self-monitoring of blood glucose in the U.S. There are also sections on the companies' histories, product lines, business and marketing analyses, and a subjective commentary on the key companies' market positions. Several subjects related to the major elements of glucose testing, disposable plastic supplies, needles, and lancets are discussed only briefly in this report because they are considered entirely different fields or markets. In-depth analysis of these areas of interest can be found in other TriMark reports at www.trimarkpublications.com, such as *Blood Glucose Testing and Diabetes Management*, *World Glucose Self-Testing Markets* and *Point of Care Diagnostic Testing World Markets*.

1.4 Methodology

The author of this report holds a Master's in immunology and has substantial experience in science writing and as a medical industry analyst. She also has many years of laboratory experience investigating cancer immunotherapies and has conducted laboratory testing and instrument and reagent development for biotech companies. The senior editor of this report holds a Ph.D. in biochemistry from the University of Minnesota and has had post-doctoral experience at the University of Connecticut School of Medicine. He has taught at Quinnipiac University and the Tufts School of Medicine, and has been a senior scientist at Pfizer Pharmaceutical Laboratories in drug development. He also has many decades of experience in science writing and as a medical industry analyst. He has over 30 years of experience in laboratory testing and instrument and reagent development technology as a licensed clinical laboratory director, as well as extensive experience in senior level management positions in biotech and medical service companies. He holds several patents on *in vitro* glucose testing.

Company-specific information is obtained mainly from industry trade publications, academic journals, news and research articles, press releases, and corporate websites, as well as annual reports for publicly-held firms. Additionally, sources of information include the non-governmental organizations (NGOs) such as the World Health Organization (WHO), governmental entities like the U.S. Department of Health and Human Services (HHS), and U.S. federal agencies such as National Institutes of Health (NIH), Food and Drug Administration (FDA), and the Centers of Disease Control and Prevention (CDC). Where possible and practicable, the most recent data available have been used.

Some of the statistical information was taken from Biotechnology Associates' databases and from TriMark's private data stores. The information in this study was obtained from sources that we believe to be reliable, but we do not guarantee the accuracy, adequacy, or completeness of any information or omission or for the results obtained by the use of such information. Key information from the business literature was used as a basis to conduct dialogue with and obtain expert opinion from market professionals regarding commercial potential and market sizes. Senior managers from major company players were interviewed for part of the information in this report.

Primary Sources

TriMark collects information from hundreds of Database Tables and many comprehensive multi-client research projects, as well as Sector Snapshots that it publishes annually. TriMark extracts relevant data and analytics from its research as part of this data collection.

Secondary Sources

TriMark uses research publications, journals, magazines, newspapers, newsletters, industry reports, investment research reports, trade and industry association reports, government-affiliated trade releases, and other published information as part of its secondary research materials. The information is then analyzed and translated by the Industry Research Group into a TriMark study. The Editorial Group reviews the complete package with product and market forecasts, critical industry trends, threats and opportunities, competitive strategies, and market share determinations.

TriMark Publications Report, Research and Data Acquisition Structure

The general sequence of research and analysis activity prior to the publication of every report in TriMark Publications includes the following items:

- Completing an extensive secondary research effort on an important market sector, including gathering all relevant information from corporate reporting, publicly-available data, and proprietary databases.
- Formulating a study outline with the assigned writer, including important items, as follows:
 - Market and product segment grouping, and evaluating their relative significance.
 - Key competitors' evaluations, including their relative positions in the business and other relevant facts to prioritize diligence levels and assist in designing a primary research strategy.

- End-user research to evaluate analytical significance in market estimation.
- Supply chain research and analysis to identify any factors affecting the market.
- New technology platforms and cutting-edge applications.
- Identifying the key technology and market trends that drive or affect these markets.
- Assessing the regional significance for each product and market segment for proper emphasis of further regional/national primary and secondary research.
- Completing a confirmatory primary research assessment of the report's findings with the assistance of expert panel partners from the industry being analyzed.

1.5 Executive Summary

Advances in diabetes treatment have revolutionized the blood glucose testing market. Direct access testing—which allows consumers to order tests themselves without visiting a doctor—has emerged as a strong force in the blood glucose testing segment. Indeed, there's an increasing range of test devices now available to consumers to perform self-testing. Moreover, automation is now a well-established trend in the central clinical laboratory, driven primarily by efforts to reduce costs, and a continuing shortage of qualified technologists and technicians. Information management, including Internet-based reporting and consultation—as well as remote data acquisition and result-reporting for POC glucose testing—is becoming a more important element of many suppliers' product offerings. The analysis and reporting of data from blood glucose tests is another area that will become increasingly important in the future.

The risk for the later development of microvascular disease makes it important to identify patients with Type 2 diabetes (sometimes referred to as adult onset diabetes). Demonstration of unequivocal hyperglycemia (plasma glucose >200 mg/dL [11.1 mmol/L]) two hours or more after a mixed meal is considered diagnostic for diabetes mellitus according to [REDACTED]. Moreover, HbA1c levels are now accepted as an indicator of diabetes. As such, frequent monitoring of blood glucose levels facilitates control of diabetes.

According to [REDACTED], there are currently an estimated [REDACTED] people ([REDACTED] diagnosed and [REDACTED] undiagnosed) in the U.S. afflicted with diabetes. An estimated [REDACTED] new cases of diabetes are diagnosed each year in the U.S. Approximately [REDACTED]% to [REDACTED]% of diabetics have Type 2 diabetes, while the rest are patients of Type 1 diabetes. The total prevalence of diagnosed diabetes in the U.S. increased by [REDACTED]% from [REDACTED] to [REDACTED]. Demographic changes, population growth, and increasing prevalence rates are equally weighted contributors to this phenomenon. Ethnic groups such as Native Americans, African Americans, and Hispanics (the latter of which are the fastest growing minority in the nation) are experiencing particularly large increases in the diabetes epidemic. The ADA estimates that the prevalence diabetes during the past few years has been approximately [REDACTED]% of the U.S. population.

In addition, approximately one in four adults ([REDACTED]) are considered to be in a “pre-diabetic” state, in which symptoms such as impaired glucose tolerance or hyperglycemia are manifested. These pre-diabetic individuals are at a significantly greater risk for developing Type 2 diabetes, heart disease, and stroke. In light of this staggering prevalence of diabetes mellitus, there is increasing demand for effective monitoring of blood glucose and tight glucose control to delay disease progression, prevent diabetic complications, and improve the quality of life for patients.

There are two key market segments for glucose testing: self-testing and professional testing. In the U.S., self-testing glucose meters and strips were worth \$ [REDACTED] in [REDACTED] and are expected to grow to over \$ [REDACTED] by [REDACTED]. The U.S. professional glucose testing market (includes central laboratory glucose testing, hospital POC glucose testing, and POC glucose testing within physicians' offices but excludes self-testing) was worth \$ [REDACTED] in [REDACTED] and is expected to increase to \$ [REDACTED] by [REDACTED]. The glucose monitoring market is dominated by the four large international companies: Roche, Johnson & Johnson (LifeScan), Bayer, and Abbott.

The sector for glucose testing devices is lucrative, but very competitive and overpopulated. Greater than █ models of hand-held blood glucose monitors are being marketed by more than █ companies for blood glucose self-testing in the U.S. In addition, there are a number of large and fully diverse diagnostic products companies that specialize in marketing clinical chemistry analyzers for the professional testing of blood glucose.

The consumable aspect of the blood glucose test strips is the primary business driver of the world glucose self-testing market. The diabetic test strip market is very large. Although unit volume growth in the U.S. market will continue to be strong, pricing pressures will push the dollar value growth to a lower pace. Sales of blood glucose testing strips across both self-testing and professional POC markets led the U.S. industry, with manufacturers' sales of over \$█ in █. The market for blood glucose test strips, which comprise nearly █% of the total North American blood glucose testing market, is expected to grow to \$█ in █, at a CAGR of █%.

Clinical chemistry analyzers are positioned in hospitals, reference labs, independent labs, regional labs, and doctor's offices. They range from the ultra-large to the small, based on their throughput (and price). Glucose testing occurs in virtually every chemistry profile put through these analyzers. The volume of glucose testing in these settings dwarfs the self-testing market in terms of numbers of tests. TriMark estimates more than █ glucose tests are performed in the U.S. on these analyzers. However, the price per test is very low, on the order of ten or █ per test, due to the efficiency of these highly engineered instruments.

The explosion of glucose monitoring devices on the market has given consumers an unprecedented choice of instruments and reagents to monitor blood glucose levels. It has also given manufacturers and developers of new technology a cohort of customers who are used to changing devices and are looking for new technologies. Underlying all of this is the classic "razor and razor blade" marketing model. Each manufacturer makes a different test strip, and they're not interchangeable from one monitor to another. Some even make a different strip for each individual monitor type. The reagents substantially drive sales, as costs and ease of use are large factors in customer choice.

Co-branding is one of the strategies that seem to offer smaller companies successful entry into the crowded glucose testing market and provides good market share. Co-branding is valuable to a device manufacturer in a number of ways:

- Manufacturers launch a co-branding program with a product line that represents the latest technology and the highest of quality standards.
- Co-branding sets the stage for a number of initiatives for other chronic disease products and services in the direct-to-consumer needs category.
- It raises the profile of smaller, less well-known companies. It leverages the marketing power of the pharmacy or retail co-branding for the small device manufacturer.

Additional recommendations include:

- Focusing diagnostic development on more effective, consumer-friendly, and affordable devices and tests for diabetes management.
- Developing better ways of monitoring glucose levels *in vivo* with continuous monitoring techniques.
- Moving to continuous glucose monitoring that may be partnered with insulin pumps to enable automated disease management using a closed loop system.
- Developing more accurate and reliable monitoring devices to take advantage of the increasing numbers of nursing home and other professional healthcare settings that are utilizing hand-held blood glucose monitoring products.
- Develop technologies (*i.e.*, mobile phone hardware and applications) that enable the increasingly tech savvy consumer base to monitor their disease.
- Focus diagnostic development on the significant and largely untapped global market that exists by creating more effective and affordable tests to manage diabetes.